Peripheral Arterial Disease study: Orforglipron
Official title Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
ClinicalTrials.gov ID: NCT07223593
What this study is testing
What is Orforglipron?
An investigational oral medicine being studied as a potential treatment for peripheral arterial disease (PAD).
Also referred to as LY3502970.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to find out how well and how safely orforglipron works when taken once a day by participants with Fontaine II peripheral arterial disease.
- Who it's for
- Adults who have Fontaine stage II peripheral arterial disease.
- What's involved
- Participants will take an oral dose of orforglipron once each day during the study.
- Time commitment
- The study lasts about 58 weeks, with regular visits as required.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Have symptomatic PAD with intermittent claudication of Fontaine Stage II
- Have an Ankle Brachial Index (ABI) of 0.9 or less
You likely can't join if
- Have a body mass index (BMI) less than 23 kilogram per square meter (kg/m2)
- Have Hemoglobin A1c (HbA1c) greater than 10%
- Have walking ability limited by conditions other than PAD
- Have a planned lower limb surgery or any other surgery affecting walking ability
- Had peripheral revascularization procedure within 90 days prior to the day of screening or planning to undergo peripheral revascularization during...
- Had stroke, transient ischemic attack, myocardial infarction, coronary or carotid revascularization, or hospitalization for unstable angina pectoris...
See the full eligibility criteria
- Have symptomatic PAD with intermittent claudication of Fontaine Stage II
- Have an Ankle Brachial Index (ABI) of 0.9 or less
- Have a body mass index (BMI) less than 23 kilogram per square meter (kg/m2)
- Have Hemoglobin A1c (HbA1c) greater than 10%
- Have walking ability limited by conditions other than PAD
- Have a planned lower limb surgery or any other surgery affecting walking ability
- Had peripheral revascularization procedure within 90 days prior to the day of screening or planning to undergo peripheral revascularization during the clinical trial
- Had stroke, transient ischemic attack, myocardial infarction, coronary or carotid revascularization, or hospitalization for unstable angina pectoris within 60 days prior to screening
- Have heart failure presently classified as being in New York Heart Association class III - IV
The study team makes the final eligibility decision.
Where it is enrolling
- Birmingham, Alabama, United States
- Gilbert, Arizona, United States
- Tucson, Arizona, United States
- Northridge, California, United States
- Redding, California, United States
- Van Nuys, California, United States
- West Hills, California, United States
- Leesburg, Florida, United States
- Miami Lakes, Florida, United States
- Saint Augustine, Florida, United States
- Hammond, Indiana, United States
- Indianapolis, Indiana, United States
- Newburgh, Indiana, United States
- Bowie, Maryland, United States
- Troy, Michigan, United States
- Camp Hill, Pennsylvania, United States
- Jackson, Tennessee, United States
- Jefferson City, Tennessee, United States
- Houston, Texas, United States
- Sherman, Texas, United States
+ 98 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Birmingham, Alabama, United States; Gilbert, Arizona, United States; Tucson, Arizona, United States; Northridge, California, United States; Redding, California, United States; Van Nuys, California, United States and 112 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.